Qiagen announced it has entered a strategic alliance with partner Sysmex for the development and commercialization of next-generation sequencing products in the area of cancer companion diagnostics.
The alliance aims to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultrasensitive liquid biopsy companion diagnostics, Qiagen said.
Qiagen and Sysmex have a long-standing partnership; the two companies provide the ipsogen JAK2 blood-cancer test in Japan.
